| Literature DB >> 19225731 |
Patricia Tschabitscher1, Irmgard Homaier, Alfred Lichtenschopf, Ernest Groman.
Abstract
Every year about 1.2 million deaths attributable to smoking occur in Europe. Effective smoking cessation, therefore, is essential. Varenicline is the first medication specifically developed for smoking cessation. The efficacy of varenicline in smoking cessation is due to its role as a partial agonist/antagonist at the alpha4beta2 nicotine receptors. This dual action causes a reduction in cigarette craving as well as withdrawal symptoms; moreover, it decreases the pleasurable and reinforcing effects of smoking. This article discusses the current clinical data regarding efficacy and safety of varenicline and its role in smoking cessation.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19225731 DOI: 10.1007/s10354-008-0636-6
Source DB: PubMed Journal: Wien Med Wochenschr ISSN: 0043-5341